Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|June 1, 2001
HAART advent shown to improve most dermatologic conditions
Vancouver, British Columbia - In his 20 years of working with HIV/AIDS patients, Alastair McLeod, M.D., has seen a dramatic change in the incidence and severity of several skin conditions common to the disease. The advent of highly active antiretroviral therapy has eliminated some conditions and greatly improved others, yet other conditions have not shown marked improvement with the drugs.
Advertisement
Advertisement
Related to this article
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
3
Tulisokibart Meets Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial
4
Repigmentation With Upadacitinib Continues Through Week 76 in Non-Segmental Vitiligo
5